Growth Metrics

Vanda Pharmaceuticals (VNDA) Net Income (2016 - 2025)

Vanda Pharmaceuticals' Net Income history spans 16 years, with the latest figure at -$141.2 million for Q4 2025.

  • On a quarterly basis, Net Income fell 2796.41% to -$141.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$220.5 million, a 1067.73% decrease, with the full-year FY2025 number at -$220.5 million, down 1066.53% from a year prior.
  • Net Income hit -$141.2 million in Q4 2025 for Vanda Pharmaceuticals, down from -$22.6 million in the prior quarter.
  • Over the last five years, Net Income for VNDA hit a ceiling of $9.6 million in Q2 2021 and a floor of -$141.2 million in Q4 2025.
  • Historically, Net Income has averaged -$9.9 million across 5 years, with a median of -$1.1 million in 2023.
  • Biggest five-year swings in Net Income: surged 1856.46% in 2021 and later tumbled 4000.73% in 2024.
  • Tracing VNDA's Net Income over 5 years: stood at $7.1 million in 2021, then fell by 3.34% to $6.9 million in 2022, then tumbled by 134.98% to -$2.4 million in 2023, then plummeted by 103.17% to -$4.9 million in 2024, then tumbled by 2796.41% to -$141.2 million in 2025.
  • Business Quant data shows Net Income for VNDA at -$141.2 million in Q4 2025, -$22.6 million in Q3 2025, and -$27.2 million in Q2 2025.